Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

remove-circle Internet Archive's in-browser video "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see your ...

Embark on a fulfilling pharmacy career with our Pharmacy Technician Training Program. Our 16-week program allows you to gain the skills required for safe patient care. The self-paced format ensures ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Carla Houser, executive director of Residential Youth Services and Empowerment, standing in a living area of the nonprofit’s first youth Sober House in Liliha, warns that the fallout from funding cuts ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

An exercise-driven course on Advanced Python Programming that was battle-tested several hundred times on the corporate-training circuit for more than a decade. Written by David Beazley, author of the ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...